- Home
- CUBI vs VERA Comparison
CUBI vs VERA Comparison
Compare CUBI & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CUBI | VERA |
|---|---|---|
| Founded | 1994 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 1.5B |
| IPO Year | 2012 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CUBI | VERA |
|---|---|---|
| Price | $76.29 | $55.40 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 11 |
| Target Price | ★ $84.14 | $76.60 |
| AVG Volume (30 Days) | 423.4K | ★ 1.9M |
| Earning Date | 01-22-2026 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.96 | N/A |
| Revenue | ★ $651,983,000.00 | N/A |
| Revenue This Year | $16.77 | N/A |
| Revenue Next Year | $6.91 | N/A |
| P/E Ratio | $15.41 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $40.75 | $18.53 |
| 52 Week High | $78.33 | $55.00 |
Technical Indicators
Market Signals| Indicator | CUBI | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 66.89 | 82.73 |
| Support Level | $75.13 | $47.22 |
| Resistance Level | $78.33 | $51.19 |
| Average True Range (ATR) | 2.08 | 2.94 |
| MACD | 0.37 | 0.63 |
| Stochastic Oscillator | 80.06 | 97.57 |
Price Performance
Historical ComparisonAbout CUBI Customers Bancorp Inc
Customers Bancorp Inc is a bank holding company engaged in banking activities. It provides financial products and services to small and middle-market businesses, not-for-profits, and consumers. The company operates in Lending Activities, Commercial Lending, Consumer Lending, Private Banking, Deposit Products, Other Funding Sources and Financial Products and Services. The majority of revenue is derived from commercial lending.
About VERA Vera Therapeutics Inc.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.